Drug Profile
Research programme: obesity and schizophrenia therapeutics - Kyoto University/Takeda
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Kyoto University; Takeda
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity; Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Obesity in Japan
- 16 Jul 2016 No recent reports of development identified for research development in Schizophrenia in Japan
- 18 Jan 2011 Early research in Obesity in Japan (unspecified route)